XBiotech
XBIT
43 hedge funds and large institutions have $33.4M invested in XBiotech in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 12 closing their positions.
226% more capital inflows, than outflows
Capital inflows: $22.5M | Capital outflows: $6.9M
42% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 12
13% more funds holding
Funds holding: 38 → 43 (+5)
3.7% more ownership
Funds ownership: 7.06% → 10.77% (+3.7%)
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
98% less call options, than puts
Call options by funds: $15K | Put options by funds: $848K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.47M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$3.31M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.26M |
| 4 |
State Street
Boston,
Massachusetts
|
+$2.19M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.75M |
| 2 |
Tibra Equities Europe
London,
United Kingdom
|
-$750K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$682K |
| 4 |
Goldman Sachs
New York
|
-$603K |
| 5 |
ExodusPoint Capital Management
New York
|
-$590K |
XBIT Hedge Fund Activity: Q2 2019 in Review
43 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q2 2019, worth a combined $33.4M — up 19% from $28.1M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XBIT positions and 12 closed out — a net gain of 5 holders — while 12 added to existing stakes and 11 trimmed.
The largest buyer was BlackRock, adding an estimated $9.47M. The largest seller was Millennium Management, cutting an estimated $1.75M.
- 43 institutional investors held XBiotech (XBIT) as of Q2 2019, up from 38 in Q1 2019.
- Funds reported $33.4M of XBiotech stock for Q2 2019, up 19% quarter-over-quarter.
- 17 funds opened new XBiotech positions in Q2 2019 and 12 closed out, a net change of +5 holders.
- The largest XBiotech buyer in Q2 2019 was BlackRock, an estimated $9.47M added.
- The largest XBiotech seller in Q2 2019 was Millennium Management, an estimated $1.75M sold.
Based on aggregated 13F filings for Q2 2019.